Masimo’s (MASI) Hold Rating Reiterated at Needham & Company LLC

Needham & Company LLC restated their hold rating on shares of Masimo (NASDAQ:MASI) in a research report released on Wednesday morning,Benzinga reports.

Several other analysts also recently weighed in on MASI. Raymond James raised shares of Masimo from a “market perform” rating to an “outperform” rating and set a $170.00 price target for the company in a research note on Wednesday. BTIG Research increased their price objective on Masimo from $166.00 to $170.00 and gave the company a “buy” rating in a research note on Monday, October 14th. Finally, Piper Sandler reiterated an “overweight” rating on shares of Masimo in a report on Friday, October 18th. Three research analysts have rated the stock with a hold rating and five have assigned a buy rating to the stock. According to data from MarketBeat, Masimo has an average rating of “Moderate Buy” and a consensus target price of $163.67.

Masimo Stock Performance

NASDAQ MASI traded up $1.06 on Wednesday, hitting $162.41. 368,946 shares of the stock traded hands, compared to its average volume of 659,362. The firm has a market capitalization of $8.64 billion, a price-to-earnings ratio of 112.01 and a beta of 0.97. Masimo has a 12 month low of $81.82 and a 12 month high of $173.90. The company has a debt-to-equity ratio of 0.50, a quick ratio of 1.15 and a current ratio of 2.01. The business’s fifty day moving average is $133.52 and its two-hundred day moving average is $126.08.

Masimo (NASDAQ:MASI) last posted its quarterly earnings data on Tuesday, November 5th. The medical equipment provider reported $0.98 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.84 by $0.14. Masimo had a return on equity of 14.98% and a net margin of 3.85%. The company had revenue of $504.60 million during the quarter, compared to analyst estimates of $502.87 million. During the same quarter last year, the company earned $0.63 earnings per share. The firm’s quarterly revenue was up 5.4% on a year-over-year basis. As a group, equities analysts anticipate that Masimo will post 4.04 EPS for the current fiscal year.

Institutional Trading of Masimo

Institutional investors have recently added to or reduced their stakes in the company. NBC Securities Inc. increased its stake in Masimo by 47.1% in the 3rd quarter. NBC Securities Inc. now owns 228 shares of the medical equipment provider’s stock worth $30,000 after buying an additional 73 shares during the period. GAMMA Investing LLC boosted its holdings in shares of Masimo by 75.0% in the second quarter. GAMMA Investing LLC now owns 259 shares of the medical equipment provider’s stock valued at $33,000 after purchasing an additional 111 shares during the period. Northwestern Mutual Wealth Management Co. grew its stake in Masimo by 133.3% in the second quarter. Northwestern Mutual Wealth Management Co. now owns 350 shares of the medical equipment provider’s stock worth $44,000 after purchasing an additional 200 shares in the last quarter. Lazard Asset Management LLC raised its position in Masimo by 5,730.0% during the 1st quarter. Lazard Asset Management LLC now owns 583 shares of the medical equipment provider’s stock valued at $85,000 after purchasing an additional 573 shares in the last quarter. Finally, HHM Wealth Advisors LLC grew its position in shares of Masimo by 25.0% during the 2nd quarter. HHM Wealth Advisors LLC now owns 625 shares of the medical equipment provider’s stock worth $79,000 after buying an additional 125 shares in the last quarter. Institutional investors own 85.96% of the company’s stock.

About Masimo

Masimo Corporation develops, manufactures, and markets various patient monitoring technologies, and automation and connectivity solutions worldwide. The company offers masimo signal extraction technology (SET) pulse oximetry with measure-through motion and low perfusion pulse oximetry monitoring to address the primary limitations of conventional pulse oximetry; Masimo rainbow SET platform, including rainbow SET Pulse CO-Oximetry products that allows noninvasive monitoring of carboxyhemoglobin, methemoglobin, hemoglobin concentration, fractional arterial oxygen saturation, oxygen content, pleth variability index, rainbow pleth variability index, respiration rate from the pleth, and oxygen reserve index, as well as acoustic respiration monitoring, SedLine brain function monitoring, NomoLine capnography and gas monitoring, and regional oximetry.